{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 69,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Clinical trial design diagram showing a 1:1 randomization between Efgartigimod and Placebo over 36 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/45",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.56,
        "x": 0.22,
        "y": 0.225
      },
      "kind": "diagram",
      "text": "Study design flow from randomization to 36-week treatment with Efgartigimod vs Placebo",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfd92a7f-602d-40c2-b179-184b0239f6cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.2,
        "x": 0.03,
        "y": 0.225
      },
      "kind": "list",
      "text": "Study Population: Bullous Pemphigoid, Moderate-to-severe disease (BPDAI activity score >= 20), Newly diagnosed and relapsing within 1 year of diagnosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b40311f-c39b-4f0a-9bc3-a2fac545a5ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.24,
        "x": 0.73,
        "y": 0.225
      },
      "kind": "list",
      "text": "Endpoints: Proposed primary endpoint (proportion of participants in complete or partial remission while off OCS), Secondary endpoints (cumulative dose of OCS, time to complete remission on minimal OCS, proportion of participants with CDA and remain free of relapse, quality of life), Followed by Open Label Extension study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32841ff4-0e0d-4f22-a285-cda00eed6c4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.45,
        "y": 0.245
      },
      "kind": "metric",
      "text": "36 weeks",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad579d39-1e27-4a3e-8e7e-bc13ecb53b39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Registrational Study of Bullous Pemphigoid to Start in 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c8058d9-80d5-4b06-9349-b6372e6ac54e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "bdf0eaf6-a19c-4786-8222-c3a166eb27af",
      "evidence": "The slide presents a clear Situation (study population and design), Complication (need for new treatments), Question (can Efgartigimod be effective?), and Answer (registrational study to start in 2021).",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "378b1b14-dd39-4ff5-8b5a-2ee121a6030e",
      "evidence": "Standardized representation of patient population, intervention, and endpoints.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}